ABSTRACT
Background: Iron deficiency anemia during pregnancy is a serious global concern specially in developing country, which is preventable with effective measures. In women who cannot tolerate oral iron or have moderate to severe anemia, parenteral iron in the form of iron sucrose or ferric carboxymaltose can be very much useful. This study aimed to compare efficacy and safety of iron sucrose and ferric carboxymaltose in iron deficiency anemia during pregnancy.Methods: This prospective interventional comparative study was conducted during May 2016 to April 2018 at tertiary care hospital and total 100 antenatal women from 28 to 34 weeks of gestation having moderate to severe anemia were included in this study and all women were divided in to 2 groups randomly and were given either iron sucrose or ferric carboxymaltose according to iron requirement. Rise in haemoglobin and serum ferritin were noted and data analysed statistically.Results: The mean rise of haemoglobin with iron sucrose was 1.8 gm% and with ferric carboxymaltose was 2.6 gm%. The mean rise of serum ferritin with iron sucrose was 82.4 ng/ml and with ferric carboxymaltose was 100.9 ng/ml. Other than minimal local reaction one woman had developed severe anaphylactic reaction after receiving iron sucrose.Conclusions: Intravenous ferric carboxymaltose is better and safe molecule than iron sucrose and it has advantage of ability to administer large dose in single sitting which reduce overall cost of therapy. Hence ferric carboxymaltose is a drug of choice as parenteral iron therapy in iron deficiency anemia during second trimester of pregnancy.
ABSTRACT
Background: In India, women become pregnant with low baseline hemoglobin level resulting in high incidence of moderate to severe anemia in pregnancy where oral iron therapy cannot meet the requirement. Pregnant women with moderate anemia are to be treated with parenteral iron therapy. The aim of the study is to the infusion of intravenous iron sucrose and its outcome in the management of anemia.Methods: Totally 100 pregnant females were included in the study. The study period was from January 2018-July 2018 at vanavil medical center in Chennai. 50 Patients of Group A was given oral iron tablets containing100mg of elemental iron. 50 patients of Group B was given a total of 1000 mg of intravenous iron sucrose divided into five doses of 200 mg each at weekly intervals. Estimation of hemoglobin was started 4 weeks after commencement of iron therapy and then repeated every 4 weeks till 36 weeks of gestation, pre-delivery and postpartum.Results: Target hemoglobin levels were achieved in 4 weeks’ time in 19 (76%) patients in the iron sucrose group as compared to 08 (32%) of patients in the oral iron group. There was a significant improvement in the various hematological parameters in iv sucrose group as compared to patients in the oral iron group. There were no significant allergic reactions in iv sucrose group.Conclusions: Our results showed that intravenous iron sucrose therapy was effective to treat moderate anemia in pregnant women. Intramuscular preparations are known to be associated with local side-effects. Iron sucrose complex iv therapy was with negligible side effects. It caused a rapid rise in hemoglobin level and the replacement of stores was faster. Long term comparative studies are required to assess if they can be used at a peripheral level.
ABSTRACT
Background: Iron deficiency anaemia (IDA) is the most common nutritional deficiency in pregnancy. Prophylactic oral iron is recommended during pregnancy to meet the increased requirement of iron. In India, more than 50% women become pregnant with low baseline haemoglobin level resulting in high incidence of moderate to severe anaemia in pregnancy where oral iron therapy cannot meet the requirement. This study was undertaken for critical evaluation of iron sucrose in terms of efficacy, safety, and feasibility along with any reduction in blood transfusion rate. Aims & Objective: To evaluate the efficacy of intravenous Iron sucrose in antenatal patients with Iron deficiency anaemia and to study the side effects of intra venous Iron sucrose. Material and Methods: This prospective study was conducted from Nov 2012 to June 2013 at VS General Hospital, Ahmedabad. 60 antenatal patients found to have anaemia having Hb level < 9 gm% were admitted and given intravenous iron sucrose therapy 100mg alternate day after calculating the dose of the iron requirement. Results: In patients having moderate anaemia (Hb 7-9 gm%), the rise in Hb found to be 2.17 ± 0.45 gm% from pre-treatment Hb of 7.88 ± 0.58 gm% to 9.9 ± 0.53 gm%. In patients with severe anaemia (Hb < 7 gm%), the rise in Hb was observed up to 2.73 ± 0.51 (SD) gm% after 1 month of iron sucrose treatment. No major side effects or anaphylactic reactions were noted during the study period. Conclusion: Parenterally administered iron sucrose elevates Hb and restores iron stores earlier and also that intravenous iron administration has led to the reduction in the rate of blood transfusion rate.